REVTx-99

Google made numerous announcements during its Made by Google event at its Bay View headquarters on Tuesday, including the release of its latest smartwatch, Pixel Watch 3, with machine learning-enabled fitness capabilities and health-metrics tracking. The Pixel Watch 3 has some fitness aspects like previous versions, such as tracking a wearer's sleep, stress levels and vitals such as oxygen, skin temperature and heart rhythm. The company said these aspects of health are interconnected. One's activity and sleep impact recovery, and recovery impacts how much activity a user can take on. The Pixel Watch 3 collects and interweaves all of that data to deliver a comprehensive profile to individuals, focused first on runners. The new health features are meant to help runners curate their workouts and reflect on their process and improvement. The wearable allows users to plan their routine, and lets them build their own workout by adding segments, setting targets for the segments and creating intervals. While the user is running, the device can be used as a coach by giving the wearer guidance through audio and haptic cues. The watch also allows for connectedness between equipment, including gym equipment like Peloton and NordicTrack. Users can follow Google Maps offline and control media playback on the workout screen, without the need to hunt for options. The tech giant also says that, with new upgrades to its sensing technology, the Pixel Watch 3 will have the most accurate heart-rate sensing technology on the market for runners. HR monitoring employs machine learning to track a user's heart rate and capture the running form of the wearer. The device can also analyze the wearer's form and dynamics, such as cadence of steps, length and height of stride and ground contact time. After a workout, a user can view performance metrics to gain insight into how to improve their fitness. The watch also analyzes and correlates workout intensity with the need for recovery. To determine if a user needs recovery time, the watch examines three biometrics: heart rate variability, resting heart rate and sleep. The device then provides a composite score that tells an individual how ready they are to take on a training load. It also includes a new metric called Cardio Mode for individuals actively training and seeking guidance. This mode tracks one's heart exertion during activity, and while going about daily life, to provide a complete overview of the wearer's training status. The Pixel Watch 3 also includes a metric called Target Mode, where users receive personalized insights about whether their body is ready to perform more training or needs time to rest and recover. Fitbit Morning Brief is another feature added to the watch that brings health information together to deliver a wearer's readiness score at the start of the day: how well they slept, tracking data against weekly exercise goals, a target load and the day's weather. Additionally, the watch includes a loss of pulse detection feature, which checks for an individual's pulse. If a pulse is not detected, the watch will call emergency services and send an automated message to alert the operator. It also goes into Auto Bedtime Mode, automatically detecting when the wearer falls asleep and turning off notifications. When a user wakes up, the watch detects the fact and automatically exits Bedtime Mode. The Pixel Watch 3 will be available in two sizes: 41 mm and 45 mm. Its displays are twice as bright as previous watches, at 2,000 nits, and can be reduced to one nit in darkroom environments. The new device will have a 35% bigger battery in the 45 mm, which allows for longer battery life, and an improved battery-saver mode that lasts up to 36 hours. The watch also charges 20% faster than previous versions. Pixel Watch 3 with a 41 mm screen will retail for $349 with WiFi capabilities, and $449 for the LTE version. The 45 mm Pixel 3 will sell for $399 with WiFi and $449 for LTE. Additional offerings Google also announced that its generative AI intelligence chatbot, Gemini Live, will be implemented in its new phones, the Pixel 9, Pixel 9 Pro and Pixel 9 Pro XL. Live allows users to have free-flowing conversations with the AI chatbot. Still, the tech giant says there are limits to how one should depend on Live's conversational AI answers. "We are very clear and upfront that Gemini should not be relied on for medical, legal, financial or other professional advice. Any content regarding those topics is provided for informational purposes only and is not a substitute for advice from a qualified professional. Gemini Live follows the same safeguards against providing detailed medical guidance as the main Gemini App experience," a Google representative told MobiHealthNews. Additionally, the company announced an updated camera system with new features for its Pixel phones, including an Add Me option, which combines Google's augmented reality platform with 15 on-device AI models. Add Me, which is launching in preview this year, allows a user to take a photo and then trade it with another person. The device's AR can guide a picture-taker in positioning a scene. Once the second shot is taken, the technology merges the two photos to create a composite image with everyone in it in one shot. An AI-enabled image generator dubbed Pixel Studio was also announced. It allows users to create and refine visuals by typing a description of what they want to see. The Pixel 9 will retail starting at $799, the Pixel 9 Pro will begin at $999, and the Pixel 9 Pro XL will start at $1,099. The company also announced the Pixel 9 Pro Fold, its premium design offering and the thinnest foldable on the market. It retails at $1,799. The tech giant announced the release of the Pixel Buds Pro 2, its first earbuds built with Gemini integration. The integration makes the offering the first device to bring Gemini outside the phone. The Buds Pro 2 will retail for $229. Consumers can preorder all the coming products starting on August 13. The HIMSS AI in Healthcare Forum is scheduled to take place September 5-6 in Boston. Learn more and register.

SAN DIEGO--( BUSINESS WIRE )--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Corporate Highlights Completed dosing of its first in human phase 1 clinical study of Gemini Announced positive phase 1 clinical data of Gemini met the primary safety endpoint and showed statistically significant biomarker activity “The Revelation team has worked hard in the first half of 2024 to continue to build the foundation for successful advancement of Gemini and we were excited to share that the primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met, a maximum tolerated dose in healthy volunteers was identified and statistically significant dose dependent upregulation of key biomarkers was observed, demonstrating the immunostimulatory preconditioning effect of Gemini,” said James Rolke, Chief Executive Officer of Revelation. “During the second half of 2024, we look forward to building on this momentum with the start of a Phase 1b study in CKD patients.” Results of Operations As of June 30, 2024, Revelation had $12.1 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through 2024. Revelation’s net cash used for operating activities for the six months ended June 30, 2024 was $5.3 million compared to net cash used for operating activities of $3.6 million for the same period in 2023. Revelation’s net loss for the three months ended June 30, 2024 was $8.4 million, or $5.13 basic and diluted net loss per share compared to a net loss of $1.4 million, or $5.83 basic and diluted net loss per share for the same period in 2023. Revelation’s net loss for the six months ended June 30, 2024 was $11.1 million, or $8.13 basic and diluted net loss per share compared to net income of $4.7 million, or $24.52 basic net earnings per share and $23.89 diluted net earnings per share for the same period in 2023, respectively. About Gemini Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®) for systemic administration. It is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of post-surgical infection (GEMINI-PSI program), as pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program). In addition, Gemini may be a treatment to stop or slow the progression of chronic kidney disease (GEMINI-CKD program). Revelation believes Gemini works through trained immunity, which redirects and attenuates the innate immune response to external stress (infection, trauma, etc.). Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. About Revelation Biosciences, Inc. Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease. For more information on Revelation, please visit www.RevBiosciences.com . Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation. REVELATION BIOSCIENCES, INC. Condensed Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 1,394,929 $ 909,278 $ 2,112,511 $ 1,434,551 General and administrative 1,127,468 1,023,752 2,312,024 2,118,326 Total operating expenses 2,522,397 1,933,030 4,424,535 3,552,877 Loss from operations (2,522,397 ) (1,933,030 ) (4,424,535 ) (3,552,877 ) Other income (expense): Change in fair value of warrant liability 4,416 423,239 72,843 8,168,174 Other income (expense), net (5,871,838 ) 61,621 (6,719,560 ) 95,728 Total other income (expense), net (5,867,422 ) 484,860 (6,646,717 ) 8,263,902 Net (loss) earnings $ (8,389,819 ) $ (1,448,170 ) $ (11,071,252 ) $ 4,711,025 Net (loss) earnings per share, basic $ (5.13 ) $ (5.83 ) $ (8.13 ) $ 24.52 Weighted-average shares used to compute net (loss) earnings per share, basic 1,635,234 248,369 1,362,534 192,149 Net (loss) earnings per share, diluted $ (5.13 ) $ (5.83 ) $ (8.13 ) $ 23.89 Weighted-average shares used to compute net (loss) earnings per share, diluted 1,635,234 248,369 1,362,534 197,167 REVELATION BIOSCIENCES, INC. Condensed Consolidated Balance Sheets June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 12,073,058 $ 11,991,701 Deferred offering costs — 71,133 Prepaid expenses and other current assets 125,743 84,691 Total current assets 12,198,801 12,147,525 Property and equipment, net 70,774 65,084 Total assets $ 12,269,575 $ 12,212,609 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,281,323 $ 1,359,898 Accrued expenses 8,454,139 1,152,460 Deferred underwriting commissions 1,382,848 2,911,260 Warrant liability 10,844 141,276 Total current liabilities 11,129,154 5,564,894 Total liabilities 11,129,154 5,564,894 Stockholders’ equity: Common Stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023 and 1,643,395 and 264,537 issued and outstanding at June 30, 2024 and December 31, 2023, respectively 1,643 265 Additional paid-in-capital 37,677,132 32,114,552 Accumulated deficit (36,538,354 ) (25,467,102 ) Total stockholders’ equity 1,140,421 6,647,715 Total liabilities and stockholders’ equity $ 12,269,575 $ 12,212,609